<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Jpn J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Jpn. J. Clin. Oncol</journal-id><journal-id journal-id-type="publisher-id">jjco</journal-id><journal-id journal-id-type="hwp">jjco</journal-id><journal-title-group><journal-title>Japanese Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0368-2811</issn><issn pub-type="epub">1465-3621</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27572087</article-id><article-id pub-id-type="pmc">5091032</article-id><article-id pub-id-type="doi">10.1093/jjco/hyw103</article-id><article-id pub-id-type="publisher-id">hyw103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tomita</surname><given-names>Yoshihiko</given-names></name><xref ref-type="aff" rid="hyw103af1">1</xref><xref ref-type="corresp" rid="hyw103cor1">*</xref><xref ref-type="author-notes" rid="hyw103fn2">12</xref></contrib><contrib contrib-type="author"><name><surname>Fukasawa</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="hyw103af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oya</surname><given-names>Mototsugu</given-names></name><xref ref-type="aff" rid="hyw103af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Uemura</surname><given-names>Hirotsugu</given-names></name><xref ref-type="aff" rid="hyw103af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Shinohara</surname><given-names>Nobuo</given-names></name><xref ref-type="aff" rid="hyw103af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Habuchi</surname><given-names>Tomonori</given-names></name><xref ref-type="aff" rid="hyw103af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rini</surname><given-names>Brian I.</given-names></name><xref ref-type="aff" rid="hyw103af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="hyw103af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Bair</surname><given-names>Angel H.</given-names></name><xref ref-type="aff" rid="hyw103af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Ozono</surname><given-names>Seiichiro</given-names></name><xref ref-type="aff" rid="hyw103af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Naito</surname><given-names>Seiji</given-names></name><xref ref-type="aff" rid="hyw103af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Akaza</surname><given-names>Hideyuki</given-names></name><xref ref-type="aff" rid="hyw103af11">11</xref></contrib><aff id="hyw103af1"><label>1</label><addr-line>Department of Urology</addr-line>, <institution>Yamagata University Faculty of Medicine</institution>, <country>Yamagata</country></aff><aff id="hyw103af2"><label>2</label><addr-line>Prostate Center and Division of Urology</addr-line>, <institution>Chiba Cancer Center</institution>, <country>Chiba</country></aff><aff id="hyw103af3"><label>3</label><addr-line>Department of Urology</addr-line>, <institution>Keio University School of Medicine</institution>, <country>Tokyo</country></aff><aff id="hyw103af4"><label>4</label><addr-line>Department of Urology</addr-line>, <institution>Kinki University School of Medicine</institution>, <country>Osaka</country></aff><aff id="hyw103af5"><label>5</label><addr-line>Department of Urology</addr-line>, <institution>Hokkaido University Graduate School of Medicine</institution>, <country>Hokkaido</country></aff><aff id="hyw103af6"><label>6</label><addr-line>Department of Urology</addr-line>, <institution>Akita University School of Medicine</institution>, <addr-line>Akita</addr-line>, <country>Japan</country></aff><aff id="hyw103af7"><label>7</label><addr-line>Department of Solid Tumor Oncology</addr-line>, <institution>Cleveland Clinic Taussig Cancer Institute</institution>, <addr-line>Cleveland</addr-line>, <addr-line>OH</addr-line></aff><aff id="hyw103af8"><label>8</label><addr-line>Pfizer Oncology</addr-line>, <addr-line>San Diego</addr-line>, <addr-line>CA</addr-line>, <country>USA</country></aff><aff id="hyw103af9"><label>9</label><addr-line>Department of Urology</addr-line>, <institution>Hamamatsu University School of Medicine</institution>, <addr-line>Shizuoka</addr-line></aff><aff id="hyw103af10"><label>10</label><addr-line>Department of Urology</addr-line>, <institution>Kyushu University</institution>, <addr-line>Graduate School of Medical Sciences</addr-line>, <addr-line>Fukuoka</addr-line></aff><aff id="hyw103af11"><label>11</label><addr-line>Strategic Investigation on Comprehensive Cancer Network</addr-line>, <addr-line>Interfaculty Initiative in Information Studies/Graduate School of Interdisciplinary Information Studies</addr-line>, <institution>The University of Tokyo</institution>, <addr-line>Tokyo</addr-line>, <country>Japan</country></aff></contrib-group><author-notes><fn id="hyw103fn1" fn-type="con"><p>This study is registered with ClinicalTrials.gov (NCT00835978).</p></fn><fn id="hyw103fn2" fn-type="con"><label>12</label><p>Present address: Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan</p></fn><corresp id="hyw103cor1"><label>*</label>For reprints and all correspondence: Yoshihiko Tomita, Department of Urology, Niigata University Graduate School of Medical and Dental Sciences, Asahimachi 1-757, Niigata 951-8510, Japan. E-mail: <email>ytomita@med.niigata-u.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>24</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>10</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>46</volume><issue>11</issue><fpage>1031</fpage><lpage>1041</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>03</day><month>6</month><year>2016</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press.</copyright-statement><copyright-year>2016</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p></license></permissions><self-uri content-type="pdf" xlink:href="hyw103.pdf"/><abstract abstract-type="precis"><p>Axitinib demonstrated clinical activity and safety in treatment-na&#x000ef;ve Japanese patients with metastatic renal cell carcinoma. Multivariate analyses identified potential predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma.</p></abstract><abstract><sec id="hyw103s1"><title>Objectives</title><p>To conduct Japanese subgroup analyses of a randomized, global Phase II study of axitinib with and without dose titration in first-line metastatic renal cell carcinoma and to explore predictive factors for axitinib efficacy in first-line metastatic renal cell carcinoma.</p></sec><sec id="hyw103s2" sec-type="methods"><title>Methods</title><p>The data included 44 Japanese and 169 non-Japanese treatment-na&#x000ef;ve patients with metastatic renal cell carcinoma. Patients received twice-daily axitinib 5 mg during a 4-week lead-in period. Patients who met the pre-defined randomization criteria were stratified by Eastern Cooperative Oncology Group performance status and randomly assigned (1:1) to axitinib or placebo titration. The primary endpoint was objective response rate; secondary endpoints included progression-free survival and safety. Predictive factors were analyzed using data from all patients.</p></sec><sec id="hyw103s3" sec-type="results"><title>Results</title><p>The objective response rate (95% confidence interval) was 66% (50&#x02013;80%) vs. 44% (36&#x02013;52%) in Japanese and non-Japanese patients, respectively. At the primary analysis, median progression-free survival could not be estimated for Japanese patients, and was 27.6 months (95% confidence interval: 16.6&#x02013;33.2) in an updated analysis. Hypertension, diarrhea, hand&#x02013;foot syndrome, dysphonia, hypothyroidism and proteinuria were common adverse events in Japanese patients. Due to a small number of randomized patients, effects of axitinib dose titration could not sufficiently be confirmed among Japanese patients. The multivariate analysis identified time from histopathological diagnosis to treatment and sum of the longest diameter for target lesion at baseline as independent predictive factors for progression-free survival.</p></sec><sec id="hyw103s4" sec-type="conclusions"><title>Conclusions</title><p>Axitinib is effective and well tolerated as first-line metastatic renal cell carcinoma therapy in Japanese patients. Predictive factors for axitinib efficacy endpoints identified in this setting warrant further investigation.</p></sec></abstract><kwd-group><kwd>axitinib</kwd><kwd>Japanese</kwd><kwd>molecular targeted therapy</kwd><kwd>renal cell carcinoma</kwd><kwd>randomized clinical trial</kwd></kwd-group><counts><page-count count="11"/></counts></article-meta></front><body><sec sec-type="intro" id="hyw103s5"><title>Introduction</title><p>Axitinib, a potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3 (<xref rid="hyw103C1" ref-type="bibr">1</xref>), showed significant improvement in progression-free survival (PFS) over sorafenib in previously treated patients with metastatic renal cell carcinoma (mRCC) in the randomized Phase III AXIS trial (<xref rid="hyw103C2" ref-type="bibr">2</xref>). Axitinib is approved for treatment of advanced second-line renal cell carcinoma (RCC) and administered at a starting dose of 5 mg twice daily (BID), which was the maximum tolerated dose determined in a Phase I dose-escalating study in patients with solid tumors (<xref rid="hyw103C3" ref-type="bibr">3</xref>). Since axitinib plasma exposure is variable among individuals, dose titration is permitted to optimize drug exposure, based on patient tolerability. The population pharmacokinetic&#x02013;pharmacodynamic analysis of pooled data from axitinib studies indicates a higher plasma exposure is associated with a higher response rate and longer survival in patients with mRCC (<xref rid="hyw103C4" ref-type="bibr">4</xref>).</p><p>To prospectively evaluate the benefit of axitinib dose titration, a randomized Phase II study was conducted in treatment-na&#x000ef;ve patients with mRCC (<xref rid="hyw103C5" ref-type="bibr">5</xref>). The objective response rate (ORR) of 54% (95% confidence interval [CI]: 40&#x02013;67%) in the axitinib-titration arm was significantly higher than the 34% (95% CI: 22&#x02013;48%) in the placebo-titration arm (<italic>P</italic>&#x000a0;=&#x000a0;0.019), supporting the clinical benefit of axitinib dose titration in a subset of patients. The study additionally showed clinical activity of axitinib in the treatment of first-line mRCC.</p><p>Efficacy and safety of axitinib in Japanese patients with previously treated mRCC has been evaluated in a limited number of clinical studies (<xref rid="hyw103C6" ref-type="bibr">6</xref>,<xref rid="hyw103C7" ref-type="bibr">7</xref>), warranting additional investigation. The aim of the current analysis was to assess the efficacy and safety of axitinib in Japanese vs. non-Japanese patients with first-line mRCC (<xref rid="hyw103C5" ref-type="bibr">5</xref>). Additionally, potential predictive factors for PFS in first-line mRCC were explored using data from the overall population. To the best of our knowledge, this is the first report of such analyses in patients with first-line mRCC treated with axitinib.</p></sec><sec sec-type="methods" id="hyw103s6"><title>Patients and methods</title><p>Details of this randomized, double-blind, placebo-controlled Phase II study of axitinib in patients with first-line mRCC, conducted in six countries, including Japan, have been previously reported (<xref rid="hyw103C5" ref-type="bibr">5</xref>). In brief, patients received axitinib 5 mg BID during a 4-week lead-in period (cycle 1); those who met the randomization criteria (Fig. <xref ref-type="fig" rid="hyw103F1">1</xref>) over 2 consecutive weeks were stratified by Eastern Cooperative Oncology Group performance status (ECOG PS) 0 vs. 1 and randomly assigned (1:1) to receive axitinib or placebo titration in 4-week cycles. Patients who did not meet the criteria continued on study (non-randomized arm). The primary endpoint was investigator-assessed ORR and secondary endpoints included PFS, overall survival (OS), safety and axitinib plasma pharmacokinetics. The study was performed with the approval of institutional review boards or independent ethics committees and in accordance with the Declaration of Helsinki, the International Conference on Harmonization Guidelines on Good Clinical Practice and applicable local regulatory requirements. Written informed consent was provided by each patient. This study is registered with ClinicalTrials.gov (NCT00835978).
<fig id="hyw103F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Study design. Doses in parenthesis indicate blinded therapy.</p></caption><graphic xlink:href="hyw103f01"/></fig></p><p>As detailed previously (<xref rid="hyw103C5" ref-type="bibr">5</xref>), patients aged &#x02265;18 years with histologically confirmed mRCC with a component of clear-cell histology, at least one measureable disease, no prior systemic therapy for mRCC, ECOG PS 0 or 1, adequate organ function and baseline blood pressure (BP) &#x02264;140/90 mmHg were eligible. Key exclusion criteria included concurrent use of more than two antihypertensive medications and brain/central nervous system metastasis. Starting on cycle 2 Day 1, randomized patients received axitinib 5 mg BID (open-label) plus axitinib 2 mg BID or placebo (blinded therapy). After &#x02265;&#x000a0;2 consecutive weeks at this dosage, patients who continued to meet the randomization criteria could have their dose increased to the maximum level of axitinib 5 mg BID plus axitinib 5 mg BID or placebo. If at any time patients experienced treatment-related toxicity, study treatment was interrupted or the dose reduced (blinded therapy first) (<xref rid="hyw103C5" ref-type="bibr">5</xref>).</p><p>Radiographic tumor assessments were performed at baseline; weeks 8, 16 and 24; and every 12 weeks thereafter, according to Response Evaluation Criteria in Solid Tumors version 1.0. Safety was monitored throughout the study and adverse events (AEs) were graded according to the Common Terminology Criteria for AEs version 3.0. BP readings were taken in clinic and at home. Serial pharmacokinetic samples were collected in a subset of patients pre-dose and 0.5, 1, 2, 4 and 6 hours post-dose on cycle 1 Day 15 (prior to dose titration: 5 mg BID) and cycle 2 Day 15 (post-dose titration: 7 mg BID). Plasma axitinib concentrations were measured using a validated high-performance liquid chromatography with tandem mass spectrometry method (<xref rid="hyw103C3" ref-type="bibr">3</xref>). Statistical analyses were previously described (<xref rid="hyw103C5" ref-type="bibr">5</xref>). Median PFS was estimated using the Kaplan&#x02013;Meier method. Axitinib pharmacokinetic parameters were estimated using non-compartmental analyses. Exploratory analyses to assess predictive factors for PFS were conducted using Cox proportional hazard model, witheach variable evaluated in the univariate analysis with Wald test. The final model was constructed by a stepwise method with a 5% level of significance.</p></sec><sec sec-type="results" id="hyw103s7"><title>Results</title><p>Of the 213 patients enrolled, 44 were Japanese and 169 were non-Japanese. All Japanese patients were enrolled at sites in Japan. Compared with non-Japanese patients, a higher percentage of Japanese patients had ECOG PS 0, smaller tumor size at baseline and fewer metastatic sites as well as fewer lymph node and adrenal metastases (Table <xref ref-type="table" rid="hyw103TB1">1</xref>). One Japanese and nine non-Japanese patients discontinued during the lead-in period. Following the lead-in period, 11 (25%) Japanese patients were randomly assigned to axitinib (<italic>n</italic>&#x000a0;=&#x000a0;6) or placebo titration (<italic>n</italic>&#x000a0;=&#x000a0;5) and the remaining 32 Japanese patients continued axitinib treatment in the non-randomized arm, whereas 50 and 51 non-Japanese patients were randomized to axitinib and placebo titration, respectively, and the remaining 59 patients to the non-randomized arm (Fig. <xref ref-type="fig" rid="hyw103F2">2</xref>). At the primary data cutoff date (12 October 2012), 48% of Japanese and 79% of non-Japanese patients discontinued treatment, mostly due to disease progression (Fig. <xref ref-type="fig" rid="hyw103F2">2</xref>). AEs were the reason for treatment discontinuation in five (11%) Japanese and 15 (9%) non-Japanese patients. Median duration of treatment was longer in Japanese vs. non-Japanese patients, respectively, in the axitinib titration (604 vs. 409 days) and the non-randomized arms (618 vs. 365 days); however, a higher percentage of Japanese than non-Japanese patients, respectively, required dose reductions (axitinib titration: 50% vs. 14%; non-randomized: 50% vs. 39%) (Table <xref ref-type="table" rid="hyw103TB2">2</xref>). The median axitinib daily dose and relative dose intensity were lower in Japanese than non-Japanese patients.
<fig id="hyw103F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>CONSORT diagram (A) Japanese and (B) non-Japanese patients.</p></caption><graphic xlink:href="hyw103f02"/></fig>
<table-wrap id="hyw103TB1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Patient demographics and baseline clinical characteristics in Japanese vs. non-Japanese patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Japanese <italic>n</italic>&#x000a0;=&#x000a0;44</th><th align="left" rowspan="1" colspan="1">Non-Japanese <italic>n</italic>&#x000a0;=&#x000a0;169</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, median (range), years</td><td rowspan="1" colspan="1">66 (42&#x02013;81)</td><td rowspan="1" colspan="1">61 (28&#x02013;87)</td><td rowspan="1" colspan="1">0.0231<sup><xref ref-type="table-fn" rid="hyw103tfn2">a</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">30 (68)</td><td rowspan="1" colspan="1">113 (67)</td><td rowspan="1" colspan="1">1.0000<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">14 (32)</td><td rowspan="1" colspan="1">56 (33)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Race, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;White</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">162 (96)</td><td rowspan="1" colspan="1">&#x0003c;0.0001<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Asian</td><td rowspan="1" colspan="1">44 (100)</td><td rowspan="1" colspan="1">2 (1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Black</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (2)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Height, mean (SD), cm</td><td rowspan="1" colspan="1">162 (9)</td><td rowspan="1" colspan="1">172 (10)</td><td rowspan="1" colspan="1">&#x0003c;0.0001<sup><xref ref-type="table-fn" rid="hyw103tfn2">a</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, mean (SD), kg</td><td rowspan="1" colspan="1">61 (12)</td><td rowspan="1" colspan="1">83 (18)</td><td rowspan="1" colspan="1">&#x0003c;0.0001<sup><xref ref-type="table-fn" rid="hyw103tfn2">a</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">ECOG PS, <italic>n</italic> (%)<sup><xref ref-type="table-fn" rid="hyw103tfn4">c</xref></sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;0</td><td rowspan="1" colspan="1">37 (84)</td><td rowspan="1" colspan="1">99 (59)</td><td rowspan="1" colspan="1">0.0015<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;1</td><td rowspan="1" colspan="1">7 (16)</td><td rowspan="1" colspan="1">70 (41)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prior nephrectomy, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">37 (84)</td><td rowspan="1" colspan="1">146 (86)</td><td rowspan="1" colspan="1">0.8077<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">7 (16)</td><td rowspan="1" colspan="1">23 (14)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No. of metastatic sites, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td rowspan="1" colspan="1">17 (39)</td><td rowspan="1" colspan="1">24 (14)</td><td rowspan="1" colspan="1">0.0003<sup><xref ref-type="table-fn" rid="hyw103tfn5">d</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td rowspan="1" colspan="1">13 (30)</td><td rowspan="1" colspan="1">44 (26)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3</td><td rowspan="1" colspan="1">6 (14)</td><td rowspan="1" colspan="1">46 (27)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;4</td><td rowspan="1" colspan="1">8 (18)</td><td rowspan="1" colspan="1">55 (33)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Metastatic sites (lung vs. lung + others), <italic>n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lung only</td><td rowspan="1" colspan="1">9 (20)</td><td rowspan="1" colspan="1">16 (9)</td><td rowspan="1" colspan="1">0.0627<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lung&#x000a0;+&#x000a0;others</td><td rowspan="1" colspan="1">35 (80)</td><td rowspan="1" colspan="1">153 (91)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Metastatic sites (individual), <italic>n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lung</td><td rowspan="1" colspan="1">30 (68)</td><td rowspan="1" colspan="1">119 (70)</td><td rowspan="1" colspan="1">0.8538<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lymph node</td><td rowspan="1" colspan="1">13 (30)</td><td rowspan="1" colspan="1">86 (51)</td><td rowspan="1" colspan="1">0.0169<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Kidney</td><td rowspan="1" colspan="1">13 (30)</td><td rowspan="1" colspan="1">37 (22)</td><td rowspan="1" colspan="1">0.3194<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Liver</td><td rowspan="1" colspan="1">6 (14)</td><td rowspan="1" colspan="1">47 (28)</td><td rowspan="1" colspan="1">0.0766<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Adrenal</td><td rowspan="1" colspan="1">3 (7)</td><td rowspan="1" colspan="1">46 (27)</td><td rowspan="1" colspan="1">0.0042<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Bone</td><td rowspan="1" colspan="1">7 (16)</td><td rowspan="1" colspan="1">30 (18)</td><td rowspan="1" colspan="1">1.0000<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Pancreas</td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">4 (2)</td><td rowspan="1" colspan="1">1.0000<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Time from histopathological diagnosis to treatment, median (range), weeks</td><td rowspan="1" colspan="1">56 (0.1&#x02013;952)</td><td rowspan="1" colspan="1">23 (0.1&#x02013;1338)</td><td rowspan="1" colspan="1">0.9223<sup><xref ref-type="table-fn" rid="hyw103tfn6">e</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Time from metastatic diagnosis to treatment, median (range), weeks</td><td rowspan="1" colspan="1">7 (0.9&#x02013;263)</td><td rowspan="1" colspan="1">8 (0.7&#x02013;456)</td><td rowspan="1" colspan="1">0.4476<sup><xref ref-type="table-fn" rid="hyw103tfn6">e</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Sum of longest diameter for target lesion, median (range), mm</td><td rowspan="1" colspan="1">75 (10&#x02013;376)</td><td rowspan="1" colspan="1">99 (10&#x02013;466)</td><td rowspan="1" colspan="1">0.0013<sup><xref ref-type="table-fn" rid="hyw103tfn6">e</xref></sup></td></tr><tr><td align="left" colspan="4" rowspan="1">Presence of metastases (<italic>de novo</italic>) at initial diagnosis, <italic>n</italic> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">25 (57)</td><td rowspan="1" colspan="1">94 (56)</td><td rowspan="1" colspan="1">1.0000<sup><xref ref-type="table-fn" rid="hyw103tfn3">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">19 (43)</td><td rowspan="1" colspan="1">75 (44)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="hyw103tfn1"><p>ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation.</p></fn><fn id="hyw103tfn2"><p><sup>a</sup>Using t-test.</p></fn><fn id="hyw103tfn3"><p><sup>b</sup>Using Fisher's exact test.</p></fn><fn id="hyw103tfn4"><p><sup>c</sup>Per case report forms and the last measure taken prior to dosing. One non-Japanese patient had ECOG PS 2.</p></fn><fn id="hyw103tfn5"><p><sup>d</sup>Using Cochran-Armitage trend exact test.</p></fn><fn id="hyw103tfn6"><p><sup>e</sup>Using Wilcoxon test.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="hyw103TB2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Exposure to study drug in Japanese vs. non-Japanese patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Japanese</th><th align="left" colspan="3" rowspan="1">Non-Japanese</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Axitinib titration</th><th align="left" rowspan="1" colspan="1">Placebo titration</th><th align="left" rowspan="1" colspan="1">Non-randomized</th><th align="left" rowspan="1" colspan="1">Axitinib titration</th><th align="left" rowspan="1" colspan="1">Placebo titration</th><th align="left" rowspan="1" colspan="1">Non-randomized</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;6</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;5</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;32</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;50</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;51</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;59</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Days on study<sup><xref ref-type="table-fn" rid="hyw103tfn7">a</xref></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">604</td><td rowspan="1" colspan="1">315</td><td rowspan="1" colspan="1">618</td><td rowspan="1" colspan="1">409</td><td rowspan="1" colspan="1">392</td><td rowspan="1" colspan="1">365</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Range</td><td rowspan="1" colspan="1">106&#x02013;657</td><td rowspan="1" colspan="1">305&#x02013;591</td><td rowspan="1" colspan="1">64&#x02013;816</td><td rowspan="1" colspan="1">42&#x02013;1062</td><td rowspan="1" colspan="1">43&#x02013;1075</td><td rowspan="1" colspan="1">33&#x02013;1089</td></tr><tr><td align="left" rowspan="1" colspan="1">Days on drug<sup><xref ref-type="table-fn" rid="hyw103tfn8">b</xref></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">578</td><td rowspan="1" colspan="1">305</td><td rowspan="1" colspan="1">530</td><td rowspan="1" colspan="1">385</td><td rowspan="1" colspan="1">369</td><td rowspan="1" colspan="1">358</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Range</td><td rowspan="1" colspan="1">91&#x02013;636</td><td rowspan="1" colspan="1">229&#x02013;591</td><td rowspan="1" colspan="1">46&#x02013;787</td><td rowspan="1" colspan="1">38&#x02013;990</td><td rowspan="1" colspan="1">43&#x02013;1073</td><td rowspan="1" colspan="1">4&#x02013;1084</td></tr><tr><td align="left" rowspan="1" colspan="1">Dose reduced &#x0003c;5 mg BID, <italic>n</italic> (%) </td><td rowspan="1" colspan="1">3 (50)</td><td rowspan="1" colspan="1">1 (20)</td><td rowspan="1" colspan="1">16 (50)</td><td rowspan="1" colspan="1">7 (14)</td><td rowspan="1" colspan="1">4 (8)</td><td rowspan="1" colspan="1">23 (39)</td></tr><tr><td align="left" colspan="3" rowspan="1">Average daily dose administered, mg<sup><xref ref-type="table-fn" rid="hyw103tfn9">c</xref></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">9.7</td><td rowspan="1" colspan="1">13.4</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">13.6</td><td rowspan="1" colspan="1">17.3</td><td rowspan="1" colspan="1">9.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Range</td><td rowspan="1" colspan="1">8.3&#x02013;13.9</td><td rowspan="1" colspan="1">8.0&#x02013;18.6</td><td rowspan="1" colspan="1">3.9&#x02013;10.4</td><td rowspan="1" colspan="1">5.2&#x02013;19.5</td><td rowspan="1" colspan="1">7.4&#x02013;19.5</td><td rowspan="1" colspan="1">4.1&#x02013;10.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Relative dose intensity, %<sup><xref ref-type="table-fn" rid="hyw103tfn10">d</xref></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median</td><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">125</td><td rowspan="1" colspan="1">78</td><td rowspan="1" colspan="1">132</td><td rowspan="1" colspan="1">171</td><td rowspan="1" colspan="1">92</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Range</td><td rowspan="1" colspan="1">80&#x02013;135</td><td rowspan="1" colspan="1">77&#x02013;186</td><td rowspan="1" colspan="1">12&#x02013;105</td><td rowspan="1" colspan="1">47&#x02013;195</td><td rowspan="1" colspan="1">65&#x02013;196</td><td rowspan="1" colspan="1">6&#x02013;100</td></tr></tbody></table><table-wrap-foot><fn id="hyw103tfn7"><p><sup>a</sup>Number of days between date of first dose and date of the last dose or data cutoff date&#x000a0;+&#x000a0;1.</p></fn><fn id="hyw103tfn8"><p><sup>b</sup>Total number of days on which axitinib was actually administered.</p></fn><fn id="hyw103tfn9"><p><sup>c</sup>Total dose administered divided by actual number of days treated.</p></fn><fn id="hyw103tfn10"><p><sup>d</sup>(Total dose administered&#x000a0;/&#x000a0;5 mg BID)&#x000a0;&#x000d7;&#x000a0;100.</p></fn></table-wrap-foot></table-wrap></p><p>Among Japanese patients, overall ORR was 66% (95% CI: 50&#x02013;80%) and axitinib titration resulted in a numerically higher ORR compared with placebo titration (67% vs. 40%, respectively). Among non-Japanese patients, overall ORR was 44% (95% CI: 36&#x02013;52%), favoring axitinib titration over placebo titration (52% vs. 33%, respectively). In the non-randomized arm, ORR in Japanese and non-Japanese patients (72% vs. 53%, respectively) was similar to the corresponding axitinib-titration arm (Table <xref ref-type="table" rid="hyw103TB3">3</xref>). The mean percentage of tumor shrinkage in the axitinib-titration arm was numerically larger in Japanese than non-Japanese patients, whereas those in the placebo titration and non-randomized arms were similar (Table <xref ref-type="table" rid="hyw103TB4">4</xref>). In the overall population, the mean percentage change from baseline in tumor size was &#x02212;34.7%, &#x02212;26.2% and &#x02212;42.7% in the axitinib titration, placebo titration and non-randomized arm, respectively. Twenty-nine Japanese patients (4 in the axitinib titration, 2 in the placebo titration and 23 in the non-randomized arm) achieved a &#x02265;30% decrease in tumor size (Fig. <xref ref-type="fig" rid="hyw103F3">3</xref>).
<fig id="hyw103F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Maximum percentage change from baseline in tumor size in Japanese patients. The dotted line indicates a 30% decrease in tumor size.</p></caption><graphic xlink:href="hyw103f03"/></fig>
<table-wrap id="hyw103TB3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Best response by RECIST in Japanese vs. non-Japanese patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="4" rowspan="1">Japanese</th><th align="left" colspan="4" rowspan="1">Non-Japanese</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Total<sup><xref ref-type="table-fn" rid="hyw103tfn12">a</xref></sup></th><th align="left" rowspan="1" colspan="1">Axitinib titration</th><th align="left" rowspan="1" colspan="1">Placebo titration</th><th align="left" rowspan="1" colspan="1">Non-randomized</th><th align="left" rowspan="1" colspan="1">Total<sup><xref ref-type="table-fn" rid="hyw103tfn13">b</xref>,<xref ref-type="table-fn" rid="hyw103tfn14">c</xref></sup></th><th align="left" rowspan="1" colspan="1">Axitinib titration</th><th align="left" rowspan="1" colspan="1">Placebo titration<sup><xref ref-type="table-fn" rid="hyw103tfn14">c</xref></sup></th><th align="left" rowspan="1" colspan="1">Non-randomized</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;44</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;6</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;5</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;32</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;169</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;50</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;51</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;59</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Best response, <italic>n</italic> (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CR</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (1)</td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PR </td><td rowspan="1" colspan="1">29 (66)</td><td rowspan="1" colspan="1">4 (67)</td><td rowspan="1" colspan="1">2 (40)</td><td rowspan="1" colspan="1">23 (72)</td><td rowspan="1" colspan="1">73 (43)</td><td rowspan="1" colspan="1">25 (50)</td><td rowspan="1" colspan="1">17 (33)</td><td rowspan="1" colspan="1">31 (53)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;SD</td><td rowspan="1" colspan="1">13 (30)</td><td rowspan="1" colspan="1">2 (33)</td><td rowspan="1" colspan="1">3 (60)</td><td rowspan="1" colspan="1">8 (25)</td><td rowspan="1" colspan="1">47 (28)</td><td rowspan="1" colspan="1">11 (22)</td><td rowspan="1" colspan="1">21 (41)</td><td rowspan="1" colspan="1">15 (25)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PD</td><td rowspan="1" colspan="1">2 (5)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (3)</td><td rowspan="1" colspan="1">36 (21)</td><td rowspan="1" colspan="1">13 (26)</td><td rowspan="1" colspan="1">11 (22)</td><td rowspan="1" colspan="1">10 (17)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Not assessed</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">9 (5)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">2 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Indeterminate</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (1)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">ORR, %<sup><xref ref-type="table-fn" rid="hyw103tfn15">d</xref></sup></td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">40</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">53</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;95% CI<sup><xref ref-type="table-fn" rid="hyw103tfn16">e</xref></sup></td><td rowspan="1" colspan="1">50&#x02013;80</td><td rowspan="1" colspan="1">22&#x02013;96</td><td rowspan="1" colspan="1">5&#x02013;85</td><td rowspan="1" colspan="1">53&#x02013;86</td><td rowspan="1" colspan="1">36&#x02013;52</td><td rowspan="1" colspan="1">37&#x02013;66</td><td rowspan="1" colspan="1">21&#x02013;48</td><td rowspan="1" colspan="1">39&#x02013;66</td></tr></tbody></table><table-wrap-foot><fn id="hyw103tfn11"><p>CR, complete response; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; CI, confidence interval.</p></fn><fn id="hyw103tfn12"><p><sup>a</sup>Includes one patient who received treatment and withdrew during the lead-in period.</p></fn><fn id="hyw103tfn13"><p><sup>b</sup>Includes nine patients who received treatment and withdrew during the lead-in period.</p></fn><fn id="hyw103tfn14"><p><sup>c</sup>One patient in placebo-titration arm did not have measurable disease at baseline.</p></fn><fn id="hyw103tfn15"><p><sup>d</sup>CR plus PR.</p></fn><fn id="hyw103tfn16"><p><sup>e</sup>Using exact method based on F distribution.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="hyw103TB4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Tumor shrinkage in Japanese vs. non-Japanese patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="4" rowspan="1">Japanese</th><th align="left" colspan="4" rowspan="1">Non-Japanese</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Total<sup><xref ref-type="table-fn" rid="hyw103tfn17">a</xref></sup></th><th align="left" rowspan="1" colspan="1">Axitinib titration</th><th align="left" rowspan="1" colspan="1">Placebo titration</th><th align="left" rowspan="1" colspan="1">Non-randomized</th><th align="left" rowspan="1" colspan="1">Total<sup><xref ref-type="table-fn" rid="hyw103tfn18">b</xref>,<xref ref-type="table-fn" rid="hyw103tfn19">c</xref>,<xref ref-type="table-fn" rid="hyw103tfn20">d</xref></sup></th><th align="left" rowspan="1" colspan="1">Axitinib titration<sup><xref ref-type="table-fn" rid="hyw103tfn20">d</xref></sup></th><th align="left" rowspan="1" colspan="1">Placebo titration<sup><xref ref-type="table-fn" rid="hyw103tfn19">c</xref>,<xref ref-type="table-fn" rid="hyw103tfn20">d</xref></sup></th><th align="left" rowspan="1" colspan="1">Non-randomized<sup><xref ref-type="table-fn" rid="hyw103tfn20">d</xref></sup></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;44</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;6</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;5</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;32</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;169</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;50</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;51</th><th align="left" rowspan="1" colspan="1"><italic>n</italic>&#x000a0;=&#x000a0;59</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1">Change from baseline in sum of tumor diameter for target lesion (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mean</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;40.2</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;41.6</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;27.5</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;43.0</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;33.9</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;33.8</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;26.1</td><td align="char" char="." rowspan="1" colspan="1">&#x02212;42.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;SD </td><td align="char" char="." rowspan="1" colspan="1">23.2</td><td align="char" char="." rowspan="1" colspan="1">19.5</td><td align="char" char="." rowspan="1" colspan="1">16.3</td><td align="char" char="." rowspan="1" colspan="1">23.9</td><td align="char" char="." rowspan="1" colspan="1">37.3</td><td align="char" char="." rowspan="1" colspan="1">41.9</td><td align="char" char="." rowspan="1" colspan="1">36.9</td><td align="char" char="." rowspan="1" colspan="1">31.7</td></tr></tbody></table><table-wrap-foot><fn id="hyw103tfn17"><p><sup>a</sup>Includes one patient who received treatment and withdrew during the lead-in period.</p></fn><fn id="hyw103tfn18"><p><sup>b</sup>Includes nine patients who received treatment and withdrew during the lead-in period.</p></fn><fn id="hyw103tfn19"><p><sup>c</sup>One patient in placebo-titration arm did not have measurable disease at baseline.</p></fn><fn id="hyw103tfn20"><p><sup>d</sup>Data are missing for 12, one, three and two patients in the total, axitinib titration, placebo titration and non-randomized arm, respectively.</p></fn></table-wrap-foot></table-wrap></p><p>At the time of the primary endpoint analysis, median PFS could not be estimated for Japanese patients (95% CI: 16.6 months to not estimable) since only 18 events had occurred, compared with 12.2 months (95% CI: 10.1&#x02013;16.4 months) among non-Japanese patients (Fig. <xref ref-type="fig" rid="hyw103F4">4</xref>A). In the updated analysis (data cutoff date, 17 May 2013) conducted in Japanese patients only, 23 patients had events and median PFS was 27.6 months (95% CI: 16.6&#x02013;33.2 months; Fig. <xref ref-type="fig" rid="hyw103F4">4</xref>B). OS data were not mature in Japanese patients at the primary or follow-up analyses (12 of 44 patients died).
<fig id="hyw103F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Kaplan&#x02013;Meier estimates of progression-free survival (PFS) in (A) Japanese vs. non-Japanese patients at 12 October 2012 data cutoff, and (B) Japanese patients at 17 May 2013 data cutoff. NE, not estimable.</p></caption><graphic xlink:href="hyw103f04"/></fig></p><p>Hypertension and diarrhea were the most common all-causality AEs in both Japanese and non-Japanese patients (Table <xref ref-type="table" rid="hyw103TB5">5</xref>). The nature of common AEs was generally similar between Japanese and non-Japanese patients, but incidence rates of some AEs, including hypertension, hand&#x02013;foot syndrome, dysphonia, hypothyroidism and proteinuria, were higher in Japanese patients and more Japanese than non-Japanese patients, respectively, received antihypertensive (95% vs. 64%) and hypothyroidism (64% vs. 32%) medications. Among Japanese patients, hypothyroidism and decreased appetite were more common with axitinib titration vs. placebo titration, whereas dysphonia, proteinuria and headache were more common in the placebo-titration vs. axitinib-titration arms (Table <xref ref-type="table" rid="hyw103TB6">6</xref>).
<table-wrap id="hyw103TB5" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Common treatment-emergent, all-causality AEs reported by all Japanese vs. non-Japanese patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char=" " span="1"/><col align="char" char="(" span="1"/><col align="char" char=" " span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">AE, <italic>n</italic> (%)<sup><xref ref-type="table-fn" rid="hyw103tfn22">a</xref></sup></th><th align="left" colspan="2" rowspan="1">Japanese<italic>n</italic>&#x000a0;=&#x000a0;44</th><th align="left" colspan="2" rowspan="1">Non-Japanese <italic>n</italic>&#x000a0;=&#x000a0;169</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">All-grade</th><th align="left" rowspan="1" colspan="1">Grade 3/4</th><th align="left" rowspan="1" colspan="1">All-grade</th><th align="left" rowspan="1" colspan="1">Grade 3/4</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">40 (91)<sup><xref ref-type="table-fn" rid="hyw103tfn23">b</xref></sup></td><td rowspan="1" colspan="1">29 (66)<sup><xref ref-type="table-fn" rid="hyw103tfn23">b</xref></sup></td><td rowspan="1" colspan="1">98 (58)</td><td rowspan="1" colspan="1">34 (20)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td rowspan="1" colspan="1">33 (75)</td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">94 (56)</td><td rowspan="1" colspan="1">16 (9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hand&#x02013;foot syndrome</td><td rowspan="1" colspan="1">32 (73)<sup><xref ref-type="table-fn" rid="hyw103tfn23">b</xref></sup></td><td rowspan="1" colspan="1">6 (14)</td><td rowspan="1" colspan="1">36 (21)</td><td rowspan="1" colspan="1">2 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dysphonia</td><td rowspan="1" colspan="1">30 (68)<sup><xref ref-type="table-fn" rid="hyw103tfn23">b</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">55 (33)</td><td rowspan="1" colspan="1">2 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypothyroidism</td><td rowspan="1" colspan="1">30 (68)<sup><xref ref-type="table-fn" rid="hyw103tfn23">b</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">44 (26)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Proteinuria</td><td rowspan="1" colspan="1">27 (61)<sup><xref ref-type="table-fn" rid="hyw103tfn23">b</xref></sup></td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">36 (21)</td><td rowspan="1" colspan="1">2 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Decreased appetite</td><td rowspan="1" colspan="1">21 (48)</td><td rowspan="1" colspan="1">3 (7)</td><td rowspan="1" colspan="1">55 (33)</td><td rowspan="1" colspan="1">4 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td rowspan="1" colspan="1">21 (48)</td><td rowspan="1" colspan="1">2 (5)</td><td rowspan="1" colspan="1">83 (49)</td><td rowspan="1" colspan="1">12 (7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stomatitis</td><td rowspan="1" colspan="1">15 (34)<sup><xref ref-type="table-fn" rid="hyw103tfn23">b</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">15 (9)</td><td rowspan="1" colspan="1">1 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nasopharyngitis</td><td rowspan="1" colspan="1">14 (32)<sup><xref ref-type="table-fn" rid="hyw103tfn23">b</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">8 (5)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight decreased</td><td rowspan="1" colspan="1">13 (30)</td><td rowspan="1" colspan="1">2 (5)</td><td rowspan="1" colspan="1">40 (24)</td><td rowspan="1" colspan="1">11 (7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dysgeusia</td><td rowspan="1" colspan="1">12 (27)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">23 (14)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td rowspan="1" colspan="1">11 (25)</td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">62 (37)</td><td rowspan="1" colspan="1">4 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Alopecia</td><td rowspan="1" colspan="1">9 (20)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">10 (6)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td rowspan="1" colspan="1">9 (20)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">39 (23)</td><td rowspan="1" colspan="1">1 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Epistaxis</td><td rowspan="1" colspan="1">9 (20)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">9 (5)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">8 (18)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">40 (24)</td><td rowspan="1" colspan="1">2 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td rowspan="1" colspan="1">4 (9)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">49 (29)</td><td rowspan="1" colspan="1">4 (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnea</td><td rowspan="1" colspan="1">4 (9)</td><td rowspan="1" colspan="1">1 (2)</td><td rowspan="1" colspan="1">36 (21)</td><td rowspan="1" colspan="1">5 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pain in extremity</td><td rowspan="1" colspan="1">3 (7)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">34 (20)</td><td rowspan="1" colspan="1">2 (1)</td></tr></tbody></table><table-wrap-foot><fn id="hyw103tfn21"><p>AE, adverse event.</p></fn><fn id="hyw103tfn22"><p><sup>a</sup>Reported by &#x02265;20% of either Japanese or non-Japanese patients.</p></fn><fn id="hyw103tfn23"><p><sup>b</sup>&#x02265;20% higher in Japanese than non-Japanese patients.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="hyw103TB6" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Common treatment-emergent, all-causality AEs reported by Japanese patients in each treatment arm</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" char="(" span="1"/><col align="char" char=" " span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">AE, <italic>n</italic> (%)<sup><xref ref-type="table-fn" rid="hyw103tfn24">a</xref></sup></th><th align="left" colspan="2" rowspan="1">Axitinib titration <italic>n</italic>&#x000a0;=&#x000a0;6</th><th align="left" colspan="2" rowspan="1">Placebo titration <italic>n</italic>&#x000a0;=&#x000a0;5</th><th align="left" colspan="2" rowspan="1">Non-randomized <italic>n</italic>&#x000a0;=&#x000a0;32</th></tr><tr><th align="left" rowspan="1" colspan="1">All-grade</th><th align="left" rowspan="1" colspan="1">Grade 3/4</th><th align="left" rowspan="1" colspan="1">All-grade</th><th align="left" rowspan="1" colspan="1">Grade 3/4</th><th align="left" rowspan="1" colspan="1">All-grade</th><th align="left" rowspan="1" colspan="1">Grade 3/4</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">5 (83)</td><td rowspan="1" colspan="1">3 (50)</td><td rowspan="1" colspan="1">5 (100)</td><td rowspan="1" colspan="1">2 (40)</td><td rowspan="1" colspan="1">29 (91)</td><td rowspan="1" colspan="1">23 (72)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td rowspan="1" colspan="1">5 (83)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">5 (100)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">23 (72)</td><td rowspan="1" colspan="1">1 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypothyroidism</td><td rowspan="1" colspan="1">5 (83)<sup><xref ref-type="table-fn" rid="hyw103tfn25">b</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (60)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">22 (69)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Hand&#x02013;foot syndrome</td><td rowspan="1" colspan="1">5 (83)</td><td rowspan="1" colspan="1">1 (17)</td><td rowspan="1" colspan="1">5 (100)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">22 (69)</td><td rowspan="1" colspan="1">5 (16)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dysphonia</td><td rowspan="1" colspan="1">4 (67)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">5 (100)<sup><xref ref-type="table-fn" rid="hyw103tfn26">c</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">21 (66)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Proteinuria</td><td rowspan="1" colspan="1">3 (50)</td><td rowspan="1" colspan="1">1 (17)</td><td rowspan="1" colspan="1">4 (80)<sup><xref ref-type="table-fn" rid="hyw103tfn26">c</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">20 (63)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td rowspan="1" colspan="1">3 (50)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (60)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">15 (47)</td><td rowspan="1" colspan="1">2 (6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Decreased appetite</td><td rowspan="1" colspan="1">5 (83)<sup><xref ref-type="table-fn" rid="hyw103tfn25">b</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (60)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">13 (41)</td><td rowspan="1" colspan="1">3 (9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nasopharyngitis</td><td rowspan="1" colspan="1">1 (17)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (20)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">12 (38)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Stomatitis</td><td rowspan="1" colspan="1">2 (33)</td><td align="left" rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (40)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">11 (34)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Alopecia</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">9 (28)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Epistaxis</td><td rowspan="1" colspan="1">1 (17)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">8 (25)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperuricemia</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">8 (25)</td><td rowspan="1" colspan="1">1 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight decreased</td><td rowspan="1" colspan="1">3 (50)</td><td rowspan="1" colspan="1">1 (17)</td><td rowspan="1" colspan="1">2 (40)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">8 (25)</td><td rowspan="1" colspan="1">1 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dysgeusia</td><td rowspan="1" colspan="1">3 (50)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (40)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">7 (22)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (20)<sup><xref ref-type="table-fn" rid="hyw103tfn26">c</xref></sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">7 (22)</td><td rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td rowspan="1" colspan="1">2 (33)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (40)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">7 (22)</td><td rowspan="1" colspan="1">1 (3)</td></tr></tbody></table><table-wrap-foot><fn id="hyw103tfn24"><p><sup>a</sup>Reported by &#x02265;20% of patients in the non-randomized arm.</p></fn><fn id="hyw103tfn25"><p><sup>b</sup>&#x02265;20% higher in the axitinib-titration than the placebo-titration arm.</p></fn><fn id="hyw103tfn26"><p><sup>c</sup>&#x02265;20% higher in the placebo-titration than the axitinib-titration arm.</p></fn></table-wrap-foot></table-wrap></p><p>The range for the maximum observed plasma concentration (C<sub>max</sub>) and area under the plasma concentration&#x02013;time curve from time zero to last time of measurable concentration (AUC<sub>last</sub>) of axitinib on cycle 1 Day 15 (i.e. at steady-state prior to dose titration) in Japanese patients generally overlapped with those in non-Japanese patients (Fig. <xref ref-type="fig" rid="hyw103F5">5</xref>). Dose titration from 5 mg BID to 7 mg BID generally resulted in increased axitinib plasma exposure (Fig. <xref ref-type="fig" rid="hyw103F6">6</xref>). The median C<sub>max</sub> and AUC<sub>last</sub>, respectively, in 10 patients, including two Japanese, increased from 40.8 ng/ml and 101 ng&#x000b7;h/ml before the dose titration to 48.3 ng/ml and 136 ng&#x000b7;h/ml following the dose titration. Based on the limited patient data, axitinib pharmacokinetic parameters for Japanese patients were within the range of those for non-Japanese patients.
<fig id="hyw103F5" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Pharmacokinetics of axitinib on cycle 1 Day 15 in a subset of Japanese and non-Japanese patients following 5 mg twice daily administration.</p></caption><graphic xlink:href="hyw103f05"/></fig>
<fig id="hyw103F6" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Pharmacokinetics of axitinib prior to dose titration (5 mg twice daily) and post dose titration (7 mg twice daily).</p></caption><graphic xlink:href="hyw103f06"/></fig></p><p>Univariate analysis of the data in the overall population identified a significant (<italic>P</italic>&#x000a0;&#x02264;&#x000a0;0.05) association between PFS and Asian ethnicity, ECOG PS, numbers and site (lung plus others vs. lung only) of metastasis, time from histopathological diagnosis to treatment, sum of the longest diameter for target lesion (tumor size), presence of <italic>de novo</italic> metastasis at initial diagnosis and baseline hemoglobin (Table <xref ref-type="table" rid="hyw103TB7">7</xref>). In the multivariate analysis, time from histopathological diagnosis to treatment &#x0003c;1 year or sum of the longest diameter for target lesion greater than median (89 mm) at baseline remained significantly associated with shorter PFS (Table <xref ref-type="table" rid="hyw103TB7">7</xref>). In an additional univariate analysis to evaluate the effect of individual metastatic sites, results showed presence of baseline lymph node, liver and bone metastases to be potential predictors for PFS (Table <xref ref-type="table" rid="hyw103TB8">8</xref>). However, baseline lactate dehydrogenase and hemoglobin levels were found not to be substantially different between patients with or without lymph node, liver or bone metastases (<ext-link ext-link-type="uri" xlink:href="http://jjco.oxfordjournals.org/lookup/suppl/doi:10.1093/jjco/hyw103/-/DC1">Table S1</ext-link>).
<table-wrap id="hyw103TB7" orientation="portrait" position="float"><label>Table 7.</label><caption><p>Univariate and multivariate analyses of predictive factors for progression-free survival (PFS) in the overall population</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>n</italic></th><th align="left" rowspan="1" colspan="1">mPFS, mo (95% CI)</th><th align="left" rowspan="1" colspan="1">Hazard ratio (95% CI)<sup><xref ref-type="table-fn" rid="hyw103tfn28">a</xref></sup></th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value<sup><xref ref-type="table-fn" rid="hyw103tfn29">b</xref></sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Univariate analyses</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age, years </td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;65 </td><td rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">11.1 (8.3&#x02013;16.6)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;65 </td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">17.5 (13.9&#x02013;26.7)</td><td rowspan="1" colspan="1">0.73 (0.50&#x02013;1.06)</td><td rowspan="1" colspan="1">0.0941</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">143</td><td rowspan="1" colspan="1">15.7 (11.1&#x02013;22.5)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">70</td><td rowspan="1" colspan="1">13.9 (9.2&#x02013;17.4)</td><td rowspan="1" colspan="1">1.14 (0.79&#x02013;1.64)</td><td rowspan="1" colspan="1">0.4736</td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;White</td><td rowspan="1" colspan="1">162</td><td rowspan="1" colspan="1">12.8 (10.1&#x02013;16.5)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Asian</td><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">NE (14.6&#x02013;NE)</td><td rowspan="1" colspan="1">0.58 (0.36&#x02013;0.94)</td><td rowspan="1" colspan="1">0.0279</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Black</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">6.5 (1.8&#x02013;11.2)</td><td rowspan="1" colspan="1">2.67 (0.65&#x02013;10.89)</td><td rowspan="1" colspan="1">0.1709</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">23.9 (2.8&#x02013;25.1)</td><td rowspan="1" colspan="1">1.15 (0.37&#x02013;3.64)</td><td rowspan="1" colspan="1">0.8088</td></tr><tr><td align="left" rowspan="1" colspan="1">Body weight, kg</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02264;65 </td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">14.9 (8.3&#x02013;19.3)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;65 to &#x02264;76 </td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1">9.2 (5.7&#x02013;24.8)</td><td rowspan="1" colspan="1">0.93 (0.57&#x02013;1.52)</td><td rowspan="1" colspan="1">0.7736</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;76 to &#x02264;89 </td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">15.7 (11.1&#x02013;23.9)</td><td rowspan="1" colspan="1">0.88 (0.55&#x02013;1.42)</td><td rowspan="1" colspan="1">0.5957</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;89 </td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">16.6 (10.3&#x02013;25.1)</td><td rowspan="1" colspan="1">0.82 (0.51&#x02013;1.34)</td><td rowspan="1" colspan="1">0.4380</td></tr><tr><td align="left" rowspan="1" colspan="1">ECOG PS</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;0</td><td rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">16.6 (13.7&#x02013;24.8)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;&#x000a0;1</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">8.1 (4.7&#x02013;16.6)</td><td rowspan="1" colspan="1">1.58 (1.11&#x02013;2.26)</td><td rowspan="1" colspan="1">0.0115</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior nephrectomy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">183</td><td rowspan="1" colspan="1">14.6 (11.2&#x02013;19.0)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">12.7 (5.6&#x02013;22.2)</td><td rowspan="1" colspan="1">1.31 (0.79&#x02013;2.15)</td><td rowspan="1" colspan="1">0.2942</td></tr><tr><td align="left" rowspan="1" colspan="1">No. of metastatic sites</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">24.8 (13.7&#x02013;NE)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;2</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">22.2 (10.3&#x02013;27.6)</td><td rowspan="1" colspan="1">1.19 (0.67&#x02013;2.11)</td><td rowspan="1" colspan="1">0.5624</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;3</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">13.8 (7.4&#x02013;16.6)</td><td rowspan="1" colspan="1">1.97 (1.13&#x02013;3.42)</td><td rowspan="1" colspan="1">0.0166</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;4</td><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">11.1 (5.6&#x02013;16.6)</td><td rowspan="1" colspan="1">2.12 (1.24&#x02013;3.63)</td><td rowspan="1" colspan="1">0.0064</td></tr><tr><td align="left" colspan="5" rowspan="1">Metastatic sites (lung vs. lung&#x000a0;+&#x000a0;others)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lung only</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">25.1 (13.9&#x02013;NE)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lung&#x000a0;+&#x000a0;others</td><td rowspan="1" colspan="1">188</td><td rowspan="1" colspan="1">13.8 (11.1&#x02013;16.6)</td><td rowspan="1" colspan="1">1.91 (1.03&#x02013;3.54)</td><td rowspan="1" colspan="1">0.0411</td></tr><tr><td align="left" colspan="3" rowspan="1">Time from histopathological diagnosis to treatment, years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;1 </td><td rowspan="1" colspan="1">88</td><td rowspan="1" colspan="1">22.5 (16.3&#x02013;26.7)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;1 </td><td rowspan="1" colspan="1">125</td><td rowspan="1" colspan="1">10.3 (8.1&#x02013;14.5)</td><td rowspan="1" colspan="1">1.81 (1.26&#x02013;2.59)</td><td rowspan="1" colspan="1">0.0013</td></tr><tr><td align="left" colspan="3" rowspan="1">Time from metastatic diagnosis to treatment, years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;1 </td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">16.6 (8.3&#x02013;NE)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;1 </td><td rowspan="1" colspan="1">193</td><td rowspan="1" colspan="1">14.5 (11.1&#x02013;17.5)</td><td rowspan="1" colspan="1">1.15 (0.62&#x02013;2.14)</td><td rowspan="1" colspan="1">0.6563</td></tr><tr><td align="left" colspan="3" rowspan="1">Sum of longest diameter for target lesion</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02264;Median<sup><xref ref-type="table-fn" rid="hyw103tfn30">c</xref></sup></td><td rowspan="1" colspan="1">107</td><td rowspan="1" colspan="1">21.6 (13.9&#x02013;25.1)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;Median<sup><xref ref-type="table-fn" rid="hyw103tfn30">c</xref></sup></td><td rowspan="1" colspan="1">105</td><td rowspan="1" colspan="1">11.1 (7.6&#x02013;14.5)</td><td rowspan="1" colspan="1">1.74 (1.23&#x02013;2.47)</td><td rowspan="1" colspan="1">0.0018</td></tr><tr><td align="left" colspan="3" rowspan="1">Presence of metastases (<italic>de novo</italic>) at initial diagnosis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">119</td><td rowspan="1" colspan="1">16.6 (11.5&#x02013;25.1)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">12.7 (8.3&#x02013;16.6)</td><td rowspan="1" colspan="1">1.44 (1.02&#x02013;2.04)</td><td rowspan="1" colspan="1">0.0376</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline lactate dehydrogenase<sup><xref ref-type="table-fn" rid="hyw103tfn31">d</xref></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02264;1.5&#x000a0;&#x000d7;&#x000a0;ULN</td><td rowspan="1" colspan="1">198</td><td rowspan="1" colspan="1">15.7 (12.2&#x02013;19.1)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;1.5&#x000a0;&#x000d7;&#x000a0;ULN</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">2.8 (1.7&#x02013;NE)</td><td rowspan="1" colspan="1">2.12 (0.99&#x02013;4.56)</td><td rowspan="1" colspan="1">0.0536</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline hemoglobin</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;LLN</td><td rowspan="1" colspan="1">119</td><td rowspan="1" colspan="1">16.6 (13.8&#x02013;24.5)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;LLN</td><td rowspan="1" colspan="1">94</td><td rowspan="1" colspan="1">11.5 (8.1&#x02013;14.9)</td><td rowspan="1" colspan="1">1.43 (1.01&#x02013;2.03)</td><td rowspan="1" colspan="1">0.0414</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Multivariate analyses</italic><sup><xref ref-type="table-fn" rid="hyw103tfn32">e</xref></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Time from histopathological diagnosis to treatment, years</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;1 vs. &#x02265;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.66 (1.15&#x02013;2.40)</td><td rowspan="1" colspan="1">0.0068</td></tr><tr><td align="left" colspan="5" rowspan="1">Sum of longest diameter for target legion</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e;Median<sup><xref ref-type="table-fn" rid="hyw103tfn30">c</xref></sup> vs. &#x02264;Median<sup><xref ref-type="table-fn" rid="hyw103tfn30">c</xref></sup></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1.63 (1.14&#x02013;2.32)</td><td rowspan="1" colspan="1">0.0069</td></tr></tbody></table><table-wrap-foot><fn id="hyw103tfn27"><p>LLN, lower limit of normal; mPFS, median progression-free survival; NE, not estimable; ULN, upper limit of normal.</p></fn><fn id="hyw103tfn28"><p><sup>a</sup>1 equals reference.</p></fn><fn id="hyw103tfn29"><p><sup>b</sup>Using Wald test.</p></fn><fn id="hyw103tfn30"><p><sup>c</sup>Median equals 89 mm in the overall population.</p></fn><fn id="hyw103tfn31"><p><sup>d</sup>Baseline lactate dehydrogenase levels were missing for four patients.</p></fn><fn id="hyw103tfn32"><p><sup>e</sup>Final model constructed by a stepwise method with a 0.05 significance level.</p></fn></table-wrap-foot></table-wrap>
<table-wrap id="hyw103TB8" orientation="portrait" position="float"><label>Table 8.</label><caption><p>Univariate analysis of baseline individual metastatic sites for PFS in the overall population</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="char" char="." rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>n</italic></th><th align="left" rowspan="1" colspan="1">mPFS, mo (95% CI)</th><th align="left" rowspan="1" colspan="1">Hazard ratio (95% CI)<sup><xref ref-type="table-fn" rid="hyw103tfn33">a</xref></sup></th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value<sup><xref ref-type="table-fn" rid="hyw103tfn34">b</xref></sup></th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Lung metastases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">16.4 (11.1&#x02013;25.1)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">149</td><td rowspan="1" colspan="1">13.9 (11.0&#x02013;17.4)</td><td rowspan="1" colspan="1">1.21 (0.83&#x02013;1.78)</td><td rowspan="1" colspan="1">0.3220</td></tr><tr><td align="left" colspan="5" rowspan="1">Lymph node metastases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1">19.4 (13.7&#x02013;26.7)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">11.0 (8.1&#x02013;16.4)</td><td rowspan="1" colspan="1">1.79 (1.26&#x02013;2.53)</td><td rowspan="1" colspan="1">0.0010</td></tr><tr><td align="left" colspan="5" rowspan="1">Kidney metastases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">163</td><td rowspan="1" colspan="1">14.6 (11.0&#x02013;17.5)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">14.5 (11.9&#x02013;22.2)</td><td rowspan="1" colspan="1">1.01 (0.67&#x02013;1.52)</td><td rowspan="1" colspan="1">0.9743</td></tr><tr><td align="left" colspan="5" rowspan="1">Liver metastases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">160</td><td rowspan="1" colspan="1">16.6 (14.6&#x02013;24.5)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">5.5 (3.0&#x02013;11.1)</td><td rowspan="1" colspan="1">2.32 (1.60&#x02013;3.36)</td><td rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" colspan="5" rowspan="1">Adrenal metastases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">164</td><td rowspan="1" colspan="1">16.3 (11.5&#x02013;19.0)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">12.8 (7.6&#x02013;22.9)</td><td rowspan="1" colspan="1">1.14 (0.77&#x02013;1.69)</td><td rowspan="1" colspan="1">0.5248</td></tr><tr><td align="left" colspan="5" rowspan="1">Bone metastases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">176</td><td rowspan="1" colspan="1">16.6 (13.7&#x02013;22.9)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">5.6 (1.9&#x02013;12.8)</td><td rowspan="1" colspan="1">2.26 (1.50&#x02013;3.41)</td><td rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" colspan="5" rowspan="1">Pancreatic metastases</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td rowspan="1" colspan="1">208</td><td rowspan="1" colspan="1">14.5 (11.1&#x02013;16.6)</td><td rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">NE (11.5&#x02013;NE)</td><td rowspan="1" colspan="1">0.35 (0.09&#x02013;1.44)</td><td rowspan="1" colspan="1">0.1461</td></tr></tbody></table><table-wrap-foot><fn id="hyw103tfn33"><p><sup>a</sup>1 equals reference.</p></fn><fn id="hyw103tfn34"><p><sup>b</sup>Using Wald test.</p></fn></table-wrap-foot></table-wrap></p></sec><sec sec-type="discussion" id="hyw103s8"><title>Discussion</title><p>Subgroup analyses of the data from the randomized Phase II study showed that axitinib has anti-tumor activity in first-line mRCC in Japanese patients. The ORR in the axitinib-titration arm was higher than that in the placebo-titration arm among Japanese patients, consistent with the results of the overall population (<xref rid="hyw103C5" ref-type="bibr">5</xref>). Furthermore, axitinib treatment resulted in higher ORR and longer median PFS (&#x0003e;2 years) in Japanese patients compared with non-Japanese patients, which might have been due, at least in part, to a higher percentage of Japanese patients with more favorable baseline clinical characteristics (ECOG PS 0, one site of metastasis, smaller baseline tumor size and fewer lymph node or liver metastases). Axitinib plasma pharmacokinetics do not appear to contribute substantially to the differences in clinical outcomes since C<sub>max</sub> and AUC<sub>last</sub>were generally comparable between Japanese and non-Japanese patients in this study, which is in agreement with previous findings from Phase I studies of axitinib (<xref rid="hyw103C8" ref-type="bibr">8</xref>&#x02013;<xref rid="hyw103C10" ref-type="bibr">10</xref>). The comparable pharmacokinetics between Japanese and non-Japanese patients observed for axitinib in this study are similar to the results reported for other VEGFR-tyrosine kinase inhibitors (TKIs), sunitinib, sorafenib and pazopanib (<xref rid="hyw103C11" ref-type="bibr">11</xref>&#x02013;<xref rid="hyw103C13" ref-type="bibr">13</xref>). In the absence of any major racial/ethnic differences in axitinib pharmacokinetics, other patient factors and/or clinical practice would have accounted for the better clinical outcome in Japanese than non-Japanese patients. In this study, fewer Japanese than non-Japanese patients, respectively, were assigned to titration arms (25% vs. 60%) because more Japanese than non-Japanese patients, respectively, failed to meet randomization criteria (diastolic BP&#x000a0;&#x0003e;&#x000a0;90 mmHg [16% vs. 8%] or treatment-related grade 3/4 AEs [28% vs. 8%]) during the lead-in period. Additionally, despite meeting randomization criteria, more Japanese than non-Japanese patients (30% vs. 19%, respectively) were not randomized, at investigator's discretion, for reasons such as presence of multiple AEs.</p><p>While cross-study comparisons need to be interpreted with caution, median PFS of 27.6 months in axitinib-treated Japanese patients was almost twice as long as the 12.2 months reported in treatment-na&#x000ef;ve Japanese patients treated with sunitinib (<xref rid="hyw103C14" ref-type="bibr">14</xref>), and longer than those treated with other anti-angiogenic inhibitors in first- or second-line mRCC (<xref rid="hyw103C15" ref-type="bibr">15</xref>&#x02013;<xref rid="hyw103C20" ref-type="bibr">20</xref>). The results of the current study, therefore, generate a hypothesis for potential therapeutic use of axitinib in Japanese patients with first-line mRCC. It should be noted that in a randomized Phase III study of axitinib in treatment-na&#x000ef;ve patients with mRCC (one-quarter of whom were Asian), the difference in the primary endpoint of PFS between axitinib and sorafenib did not reach statistical significance in the overall population (median PFS: 10.1 vs. 6.5 months; hazard ratio 0.77 [95% CI: 0.56&#x02013;1.05]; one-sided <italic>P</italic>&#x000a0;=&#x000a0;0.038), but median PFS was significantly longer with axitinib than sorafenib in patients with ECOG PS 0 (13.7 vs. 6.6 months; hazard ratio 0.64 [95% CI: 0.42&#x02013;0.99]; one-sided <italic>P</italic>&#x000a0;=&#x000a0;0.022) (<xref rid="hyw103C21" ref-type="bibr">21</xref>).</p><p>Axitinib was reasonably well tolerated, as evidenced by treatment discontinuation due to AEs in 11% and 9% of Japanese and non-Japanese patients, respectively. Common AEs with axitinib, known class effects of antiangiogenic TKIs (<xref rid="hyw103C18" ref-type="bibr">18</xref>&#x02013;<xref rid="hyw103C20" ref-type="bibr">20</xref>), were generally similar between Japanese and non-Japanese patients and were manageable. However, the incidence of several AEs (hypertension, hand&#x02013;foot syndrome, dysphonia, hypothyroidism and proteinuria) was higher in Japanese patients. Differences in the frequency of some AEs between Asian and non-Asian patients have been described for other antiangiogenic TKIs <xref rid="hyw103C15" ref-type="bibr">(15</xref>,<xref rid="hyw103C22" ref-type="bibr">22</xref>&#x02013;<xref rid="hyw103C26" ref-type="bibr">26</xref>), which might partly be explained by differences in genetic background <xref rid="hyw103C27" ref-type="bibr">(27</xref>,<xref rid="hyw103C28" ref-type="bibr">28</xref>). Although the number of Japanese patients in each randomized arm was too small to draw any meaningful conclusion, no major differences in the safety profile were noted between the axitinib- and placebo-titration arms. The common AEs in Japanese patients in this first-line mRCC study were comparable to those reported in the second-line setting <xref rid="hyw103C6" ref-type="bibr">(6</xref>,<xref rid="hyw103C7" ref-type="bibr">7</xref>).</p><p>Based on the favorable efficacy results observed in Japanese patients, exploratory analyses were performed to investigate baseline patient characteristics that may be predictive for PFS in the overall population. Several factors (e.g. prior therapy, ECOG PS, hemoglobin level) have been identified as risk factors for PFS and/or OS in patients with second-line mRCC treated with axitinib <xref rid="hyw103C4" ref-type="bibr">(4</xref>,<xref rid="hyw103C29" ref-type="bibr">29</xref>), but there has been no report of similar analyses in first-line mRCC. In univariate analyses using data from 213 treatment-na&#x000ef;ve patients in this study, several patient baseline characteristics were found to be significantly (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) associated with median PFS. In the multivariate analysis, time from histopathological diagnosis to treatment and baseline tumor size remained as independent predictive factors. Incidentally, another multivariate analysis of pooled data in patients with mRCC (74% of whom were treatment-na&#x000ef;ve) treated with sunitinib identified time from diagnosis to treatment as one of the independent predictors for PFS (<xref rid="hyw103C30" ref-type="bibr">30</xref>). In an additional univariate analysis for individual metastatic sites in the current study, significantly shorter PFS was observed in patients with lymph node, liver or bone metastasis. However, interestingly, no significant difference was found in baseline levels of lactate dehydrogenase or hemoglobin, which are other prognostic factors used in the Memorial Sloan-Kettering Cancer Center (MSKCC) risk scoring system, between patients with and without lymph node, liver or bone metastasis. In this study, calcium concentrations were not measured; hence, the limitation of the analyses was that MSKCC or Heng risk factors (<xref rid="hyw103C31" ref-type="bibr">31</xref>) could not be included. The factors identified for PFS mostly coincide with baseline characteristics that were significantly different between Japanese and non-Japanese patients, and might explain the better clinical outcomes in Japanese patients. Therefore, the current analyses would help identify patients who would likely or unlikely benefit from axitinib treatment, not only for Japanese patients, but also non-Japanese patients.</p><p>In conclusion, axitinib was effective and well tolerated in Japanese patients with previously untreated mRCC. The time from histopathological diagnosis to treatment and baseline tumor size were found to be associated with axitinib efficacy in first-line treatment of mRCC. The predictive factors for PFS identified in the current analyses warrant further investigation.</p></sec><sec sec-type="supplementary-material" id="hyw103s10"><title>Supplementary data</title><p><ext-link ext-link-type="uri" xlink:href="http://jjco.oxfordjournals.org/lookup/suppl/doi:10.1093/jjco/hyw103/-/DC1">Supplementary data are available at http://www.jjco.oxfordjournals.org</ext-link>.</p>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_46_11_1031__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_hyw103_Tomita1046JapaneseSubgroup_JJCO_SupplementalTableS1.doc"/>
</supplementary-material>
</sec></body><back><ack id="hyw103ack1"><title>Acknowledgements</title><p>This study was sponsored by Pfizer. Pfizer was involved in study design, data collection and interpretation of data. We thank Hisanaga Ohashi of Pfizer for data collection and Hiroko Godai of Pfizer for data analysis. Medical writing support was provided by Mariko Nagashima, PhD, of Engage Scientific Solutions (Southport, CT, USA) and was funded by Pfizer.</p><sec id="hyw103s9"><title>Conflicts of interest statement</title><p>The Author Responsibility-COI forms were submitted with the manuscript.</p></sec></ack><ref-list><title>References</title><ref id="hyw103C1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu-Lowe</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Grazzini</surname><given-names>ML</given-names></name>, <etal>et al</etal></person-group>
<article-title>Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3</article-title>. <source>Clin Cancer Res</source>
<year>2008</year>;<volume>14</volume>:<fpage>7272</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">19010843</pub-id></mixed-citation></ref><ref id="hyw103C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rini</surname><given-names>BI</given-names></name>, <name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tomczak</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial</article-title>. <source>Lancet</source>
<year>2011</year>;<volume>378</volume>:<fpage>1931</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22056247</pub-id></mixed-citation></ref><ref id="hyw103C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Herbst</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results</article-title>. <source>J Clin Oncol</source>
<year>2005</year>;<volume>23</volume>:<fpage>5474</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">16027439</pub-id></mixed-citation></ref><ref id="hyw103C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rini</surname><given-names>BI</given-names></name>, <name name-style="western"><surname>Garrett</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Poland</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis</article-title>. <source>J Clin Pharmacol</source>
<year>2013</year>;<volume>53</volume>:<fpage>491</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="pmid">23553560</pub-id></mixed-citation></ref><ref id="hyw103C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rini</surname><given-names>BI</given-names></name>, <name name-style="western"><surname>Melichar</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ueda</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial</article-title>. <source>Lancet Oncol</source>
<year>2013</year>;<volume>14</volume>:<fpage>1233</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">24140184</pub-id></mixed-citation></ref><ref id="hyw103C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomita</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Uemura</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Fujimoto</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma</article-title>. <source>Eur J Cancer</source>
<year>2011</year>;<volume>47</volume>:<fpage>2592</fpage>&#x02013;<lpage>602</lpage>.<pub-id pub-id-type="pmid">21889330</pub-id></mixed-citation></ref><ref id="hyw103C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Uemura</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tomita</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial</article-title>. <source>Jpn J Clin Oncol</source>
<year>2013</year>;<volume>43</volume>:<fpage>616</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">23630366</pub-id></mixed-citation></ref><ref id="hyw103C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pithavala</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Tortorici</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Toh</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2010</year>;<volume>65</volume>:<fpage>563</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">19603168</pub-id></mixed-citation></ref><ref id="hyw103C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukohara</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nakajima</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mukai</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients</article-title>. <source>Cancer Sci</source>
<year>2010</year>;<volume>101</volume>:<fpage>963</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20180805</pub-id></mixed-citation></ref><ref id="hyw103C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kiyota</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chayahara</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients</article-title>. <source>Invest New Drugs</source>
<year>2012</year>;<volume>30</volume>:<fpage>1055</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">21301929</pub-id></mixed-citation></ref><ref id="hyw103C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirao</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nishida</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Doi</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title> Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate</article-title>. <source>Invest New Drugs</source>
<year>2010</year>;<volume>28</volume>:<fpage>866</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">19730791</pub-id></mixed-citation></ref><ref id="hyw103C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minami</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kawada</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ebi</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors</article-title>. <source>Cancer Sci</source>
<year>2008</year>;<volume>99</volume>:<fpage>1492</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18477034</pub-id></mixed-citation></ref><ref id="hyw103C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inada-Inoue</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kawada</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2014</year>;<volume>73</volume>:<fpage>673</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">24464355</pub-id></mixed-citation></ref><ref id="hyw103C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomita</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shinohara</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yuasa</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma</article-title>. <source>Jpn J Clin Oncol</source>
<year>2010</year>;<volume>40</volume>:<fpage>1166</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">20713418</pub-id></mixed-citation></ref><ref id="hyw103C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akaza</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tsukamoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Murai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nakajima</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Naito</surname><given-names>S</given-names></name></person-group>
<article-title>Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma</article-title>. <source>Jpn J Clin Oncol</source>
<year>2007</year>;<volume>37</volume>:<fpage>755</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">17951335</pub-id></mixed-citation></ref><ref id="hyw103C16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pluzanska</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koralewski</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial</article-title>. <source>Lancet</source>
<year>2007</year>;<volume>370</volume>:<fpage>2103</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">18156031</pub-id></mixed-citation></ref><ref id="hyw103C17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rini</surname><given-names>BI</given-names></name>, <name name-style="western"><surname>Halabi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>JE</given-names></name>, <etal>et al</etal></person-group>
<article-title>Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206</article-title>. <source>J Clin Oncol</source>
<year>2008</year>;<volume>26</volume>:<fpage>5422</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18936475</pub-id></mixed-citation></ref><ref id="hyw103C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Eisen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Stadler</surname><given-names>WM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title>. <source>N Engl J Med</source>
<year>2007</year>;<volume>356</volume>:<fpage>125</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">17215530</pub-id></mixed-citation></ref><ref id="hyw103C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sternberg</surname><given-names>CN</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>ID</given-names></name>, <name name-style="western"><surname>Mardiak</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</article-title>. <source>J Clin Oncol</source>
<year>2010</year>;<volume>28</volume>:<fpage>1061</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20100962</pub-id></mixed-citation></ref><ref id="hyw103C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Hutson</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Tomczak</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</article-title>. <source>N Engl J Med</source>
<year>2007</year>;<volume>356</volume>:<fpage>115</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">17215529</pub-id></mixed-citation></ref><ref id="hyw103C21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutson</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Lesovoy</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Al-Shukri</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial</article-title>. <source>Lancet Oncol</source>
<year>2013</year>;<volume>14</volume>:<fpage>1287</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">24206640</pub-id></mixed-citation></ref><ref id="hyw103C22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uemura</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shinohara</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yuasa</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety</article-title>. <source>Jpn J Clin Oncol</source>
<year>2010</year>;<volume>40</volume>:<fpage>194</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">19897852</pub-id></mixed-citation></ref><ref id="hyw103C23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea</article-title>. <source>Cancer Res Treat</source>
<year>2009</year>;<volume>41</volume>:<fpage>67</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">19707503</pub-id></mixed-citation></ref><ref id="hyw103C24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>JJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study</article-title>. <source>BMC Cancer</source>
<year>2009</year>;<volume>9</volume>:<fpage>249</fpage>.<pub-id pub-id-type="pmid">19622166</pub-id></mixed-citation></ref><ref id="hyw103C25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Sul</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>JS</given-names></name></person-group>
<article-title>Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience</article-title>. <source>Korean J Urol</source>
<year>2010</year>;<volume>51</volume>:<fpage>450</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">20664776</pub-id></mixed-citation></ref><ref id="hyw103C26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JL</given-names></name>, <etal>et al</etal></person-group>
<article-title>The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction</article-title>. <source>Jpn J Clin Oncol</source>
<year>2010</year>;<volume>40</volume>:<fpage>980</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">20457723</pub-id></mixed-citation></ref><ref id="hyw103C27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsuchiya</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Narita</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Inoue</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma</article-title>. <source>Anticancer Drugs</source>
<year>2013</year>;<volume>24</volume>:<fpage>310</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">23237922</pub-id></mixed-citation></ref><ref id="hyw103C28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>WS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2013</year>;<volume>72</volume>:<fpage>825</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">24013576</pub-id></mixed-citation></ref><ref id="hyw103C29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tomczak</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial</article-title>. <source>Lancet Oncol</source>
<year>2013</year>;<volume>14</volume>:<fpage>552</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">23598172</pub-id></mixed-citation></ref><ref id="hyw103C30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bukowski</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma</article-title>. <source>Br J Cancer</source>
<year>2013</year>;<volume>108</volume>:<fpage>2470</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">23695024</pub-id></mixed-citation></ref><ref id="hyw103C31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heng</surname><given-names>DY</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Regan</surname><given-names>MM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study</article-title>. <source>J Clin Oncol</source>
<year>2009</year>;<volume>27</volume>:<fpage>5794</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19826129</pub-id></mixed-citation></ref></ref-list><app-group><app id="x13"><title>Appendix</title><p>The following authors have contributed equally to the current study, in addition to the authors listed in the author field.</p><p>Yosuke Fujii<sup><xref ref-type="app" rid="x13">13</xref></sup>, Akiyuki Suzuki<sup><xref ref-type="app" rid="x13">13</xref></sup>, Yoichi Kamei<sup><xref ref-type="app" rid="x13">13</xref></sup>, Yoshiko Umeyama<sup><xref ref-type="app" rid="x13">13</xref></sup></p><p><sup><xref ref-type="app" rid="x13">13</xref></sup>Pfizer Japan Inc, Tokyo, Japan</p></app></app-group></back></article>